FDA to resume routine domestic surveillance inspections next week
Citing declining COVID-19 cases, a US Food and Drug Administration (FDA) spokesperson told Focus that the agency will resume its domestic surveillance inspection operations on 7 February 2022.In emailed comments to Focus, Shelly Burgess, senior media advisor within FDA’s Office of Regulatory Affairs, said the agency decided on 2 February to resume the inspections following the extended halt the agency announced last month. “Beginning on Feb. 7, the agency will resume conducting domestic surveillance inspections across all commodities given the decline in COVID-19 cases across the country,” she said.
Burgess also said that FDA continues to conduct mission-critical domestic and foreign inspections, as well as use its alternative tools and remote assessments to “provide effective oversight of foods, drugs, medical products and tobacco.”
“The agency also continues to proceed with previously planned foreign surveillance inspections that have received country clearance and are within the Center for Disease Control and Prevention’s Level 1 or Level 2 COVID-19 travel recommendation. Planning for additional foreign surveillance inspections is ongoing, with an anticipated goal of conducting foreign prioritized inspections starting in April,” Burgess said.
Just before the New Year, on 29 December, FDA temporarily halted much of its inspectional activities “to ensure the safety of its employees and those of the firms it regulates as the agency further adapts to the evolving COVID-19 pandemic and the spread of the omicron variant.” (RELATED: FDA temporarily halts inspections due to omicron, Regulatory Focus 5 January 2022)
At the time, the agency said it would halt all but mission-critical domestic and foreign inspections through 19 January, though it would “reassess plans as needed,” based on travel conditions abroad. On 19 January, Focus reported that FDA extended its temporary halt for inspections through 4 February. (RELATED: FDA extends temporary halt in inspections driven by omicron, Regulatory Focus 19 January 2022)
×
Welcome to the new RAPS Digital Experience
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.